PMID

Data

Article Title

Organization

Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.

Bristol-Myers Squibb

Carbamazepine derivatives with P2X4 receptor-blocking activity.

University of Bonn

Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.

Bristol-Myers Squibb

Synthesis and structure-activity relationships of carboxylic acid derivatives of pyridoxal as P2X receptor antagonists.

Gwangju Institute of Science and Technology

Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.

University of Bonn

Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.

Roche Palo Alto

N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists.

University of Bonn

Novel antagonists acting at the P2Y(1) purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques.

Universit£

Purine and pyrimidine (P2) receptors as drug targets.

National Institute of Diabetes

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Roche Palo Alto

Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.

Roche Palo Alto

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.

Northwest University

Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist.

Roche Palo Alto

Unveiling the Structure-Activity Relationships at the Orthosteric Binding Site of P2X Ion Channels: The Route to Selectivity.

European Institute For Molecular Imaging (Eimi)

Structure-Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2

National Institute of Diabetes and Digestive and Kidney Diseases

Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.

Shionogi

Dioxotriazine derivatives as a new class of P2X

Shionogi

Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.

University of Bonn

Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion.

Gwangju Institute of Science and Technology (Gist)

Investigation on 2',3'-

University of Camerino

Discovery and Characterization of the Potent and Selective P2X4 Inhibitor

Bayer

Novel Series of Dihydropyridinone P2X7 Receptor Antagonists.

Hoffmann-La Roche

Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells.

Gwangju Institute of Science and Technology (Gist)

Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.

Shionogi

Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease.

Yogi Vemana University

Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b.

University of Leipzig